Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion

• Status: Unknown status
• Trial end date: 2018-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Our double-blinded, randomized control trial will assess the effect of nebulized racemic epinephrine inpatients undergoing anterior cervical discectomy and fusion (ACDF) procedures. The investigators have had success in managing post-operative dysphagia in patients undergoing ACDF with the administration of this drug. Half of the participants will review nebulized epinephrine. The other half will receive placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Andrew Chung
• Collaborators: Banner Health; More Foundation
• Treatments: Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

1. Patients > 18 years of age

2. Primary two and three-level ACDF between C3-7

3. Approved pre-authorization to undergo the procedure

Exclusion Criteria:

1. Patients < 18 years of age

2. Patients who are unable to give their own consent

3. Revision ACDF

4. Combined anterior-posterior surgeries

5. Surgeries involving C2-C3 or C7-T1

6. Surgeries related to trauma, infection, or tumor

7. Patients with baseline swallowing dysfunction

8. Patients currently on steroids

9. Patients with severe cardiac disease

10. Uncontrolled diabetics as defined by patients with a HbA1C > 8%

11. Patients with known allergy to epinephrine